| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Subtotal dosage forms | — | — | — | $413.47M | $431.52M | $454.45M | $433.95M | $417.92M |
| Oral solid | — | — | — | $178.95M | $178.26M | $180.46M | $188.71M | $171.1M |
| Subtotal therapeutic classes | — | — | — | $108.3M | $127.54M | $125.24M | $166.93M | $133.27M |
| Distribution | $116.14M | $101.61M | $106.53M | $104.9M | $99.66M | $96.22M | $107.68M | $89.15M |
| Central nervous system | $63.91M | $73.4M | $76.59M | $67.61M | $83.43M | $77.63M | $104.75M | $83.38M |
| Transdermal | — | — | — | $43.06M | $40.71M | $47.6M | $56.14M | $73.96M |
| Government label | $36.21M | $41.94M | $46.86M | $50.14M | $45.42M | $87.76M | $86.79M | $59.95M |
| Injectable | — | — | — | $34.79M | $34.65M | $54.37M | $37.44M | $49.94M |
| Other dosage forms | — | — | — | $56.42M | $68.19M | $59.66M | $68.15M | $46.61M |
| Auto-Injector | — | — | — | $48.16M | $66.59M | $78.94M | $39.1M | $41.91M |
| Hormonal / allergy | $31.78M | $32.28M | $36.99M | $34.2M | $35.42M | $37.69M | $47.63M | $35.93M |
| Biosimilar | — | — | — | $28.54M | $25.25M | $17.01M | $29.43M | $22.3M |
| Other therapeutic classes | $8.36M | $7.91M | $7.25M | $6.49M | $8.7M | $9.92M | $14.55M | $13.95M |
| Oral liquid | — | — | — | $23.55M | $17.88M | $16.42M | $14.98M | $12.09M |
| Institutional | $11.77M | $9.39M | $10.73M | $11.01M | $10.13M | $5.85M | $8.38M | $9.82M |
| International | — | — | — | $1.23M | $1.9M | $6.29M | $2.7M | $5.32M |
| Total | $701.78M | $702.47M | $730.52M | $695.42M | $724.51M | $784.51M | $814.32M | $722.52M |